169 related articles for article (PubMed ID: 20584765)
1. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes.
Pinschewer DD; Flatz L; Steinborn R; Horvath E; Fernandez M; Lutz H; Suter M; Bergthaler A
Int Immunol; 2010 Sep; 22(9):749-56. PubMed ID: 20584765
[TBL] [Abstract][Full Text] [Related]
2. Envelope exchange for the generation of live-attenuated arenavirus vaccines.
Bergthaler A; Gerber NU; Merkler D; Horvath E; de la Torre JC; Pinschewer DD
PLoS Pathog; 2006 Jun; 2(6):e51. PubMed ID: 16751848
[TBL] [Abstract][Full Text] [Related]
3. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
4. General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.
Iwasaki M; Ngo N; Cubitt B; Teijaro JR; de la Torre JC
J Virol; 2015 Dec; 89(23):12166-77. PubMed ID: 26401045
[TBL] [Abstract][Full Text] [Related]
5. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652
[TBL] [Abstract][Full Text] [Related]
6. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.
Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus.
Lee AM; Cruite J; Welch MJ; Sullivan B; Oldstone MB
Virology; 2013 Aug; 442(2):114-21. PubMed ID: 23684417
[TBL] [Abstract][Full Text] [Related]
9. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
[TBL] [Abstract][Full Text] [Related]
10. Plasmid DNA vaccines are effective in the absence of IFNgamma.
Hassett DE; Zhang J; Whitton JL
Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092
[TBL] [Abstract][Full Text] [Related]
11. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
de la Torre JC
Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.
Vollstedt S; Franchini M; Alber G; Ackermann M; Suter M
J Virol; 2001 Oct; 75(20):9596-600. PubMed ID: 11559791
[TBL] [Abstract][Full Text] [Related]
13. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells.
Mueller AK; Deckert M; Heiss K; Goetz K; Matuschewski K; Schlüter D
Am J Pathol; 2007 Jul; 171(1):107-15. PubMed ID: 17591958
[TBL] [Abstract][Full Text] [Related]
14. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes.
Trimnell A; Takagi A; Gupta M; Richie TL; Kappe SH; Wang R
J Immunol; 2009 Nov; 183(9):5870-8. PubMed ID: 19812194
[TBL] [Abstract][Full Text] [Related]
15. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.
Oppliger J; Torriani G; Herrador A; Kunz S
J Virol; 2016 Jul; 90(14):6412-6429. PubMed ID: 27147735
[TBL] [Abstract][Full Text] [Related]
16. Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge.
Krolik M; Csepregi L; Hartmann F; Engetschwiler C; Flatz L
Vaccine; 2021 Feb; 39(8):1257-1264. PubMed ID: 33518468
[TBL] [Abstract][Full Text] [Related]
17. Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus.
Eschli B; Zellweger RM; Wepf A; Lang KS; Quirin K; Weber J; Zinkernagel RM; Hengartner H
J Virol; 2007 Nov; 81(21):11650-7. PubMed ID: 17699567
[TBL] [Abstract][Full Text] [Related]
18. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.
Cheng BYH; Nogales A; de la Torre JC; Martínez-Sobrido L
Virology; 2017 Jan; 501():35-46. PubMed ID: 27855284
[TBL] [Abstract][Full Text] [Related]
19. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
Iwasaki M; Cubitt B; Sullivan BM; de la Torre JC
J Virol; 2016 Jan; 90(6):3187-97. PubMed ID: 26739049
[TBL] [Abstract][Full Text] [Related]
20. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
